These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 1576659)

  • 1. Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice.
    Jabs DA; Burek CL; Hu Q; Kuppers RC; Lee B; Prendergast RA
    Cell Immunol; 1992 May; 141(2):496-507. PubMed ID: 1576659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-lpr/lpr mice.
    Jabs DA; Kuppers RC; Saboori AM; Burek CL; Enger C; Lee B; Prendergast RA
    Cell Immunol; 1994 Mar; 154(1):66-76. PubMed ID: 7907009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxic effect of anti-CD4 therapy on lacrimal gland disease in MRL/Mp-lpr/lpr mice.
    Jabs DA; Burns WH; Prendergast RA
    Invest Ophthalmol Vis Sci; 1996 Jan; 37(1):246-50. PubMed ID: 8550330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of T cells in the pathogenesis of autoimmune lacrimal gland disease in MRL/Mp-lpr/lpr mice.
    Jabs DA; Lee B; Prendergast RA
    Curr Eye Res; 1997 Sep; 16(9):909-16. PubMed ID: 9288452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of non-depleting anti-CD4 in MRL/Mp-lpr/lpr mice with active systemic lupus erythematosus and microscopic angiitis.
    Harper JM; Cook A
    Autoimmunity; 2001; 33(4):245-51. PubMed ID: 11683399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune ocular disease in MRL/Mp-lpr/lpr mice is suppressed by anti-CD4 antibody.
    Jabs DA; Prendergast RA
    Invest Ophthalmol Vis Sci; 1991 Sep; 32(10):2718-22. PubMed ID: 1680111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease.
    Seaman WE; Wofsy D; Greenspan JS; Ledbetter JA
    J Immunol; 1983 Apr; 130(4):1713-8. PubMed ID: 6187819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term anti-CD4 or anti-CD8 treatment on the development of lpr CD4- CD8- double negative T cells and of the autoimmune syndrome in MRL-lpr/lpr mice.
    Merino R; Fossati L; Iwamoto M; Takahashi S; Lemoine R; Ibnou-Zekri N; Pugliatti L; Merino J; Izui S
    J Autoimmun; 1995 Feb; 8(1):33-45. PubMed ID: 7734035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL/Mp-lpr/lpr mice.
    Jabs DA; Lee B; Burek CL; Saboori AM; Prendergast RA
    Invest Ophthalmol Vis Sci; 1996 Feb; 37(2):377-83. PubMed ID: 8603842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic treatment of C3H-lpr/lpr and C3H-gld/gld mice with anti-CD8 monoclonal antibody prevents the accumulation of double negative T cells but not autoantibody production.
    Giese T; Davidson WF
    J Immunol; 1994 Feb; 152(4):2000-10. PubMed ID: 8120404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for major alterations in the thymocyte subpopulations in murine models of autoimmune diseases.
    Kakkanaiah VN; Pyle RH; Nagarkatti M; Nagarkatti PS
    J Autoimmun; 1990 Jun; 3(3):271-88. PubMed ID: 1975741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the existence of distinct heterogeneity among the peripheral CD4-CD8- T cells from MRL-lpr/lpr mice based on the expression of the J11d marker, activation requirements, and functional properties.
    Kakkanaiah VN; Nagarkatti M; Nagarkatti PS
    Cell Immunol; 1990 May; 127(2):442-57. PubMed ID: 2139366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha.
    Edwards CK; Zhou T; Zhang J; Baker TJ; De M; Long RE; Borcherding DR; Bowlin TL; Bluethmann H; Mountz JD
    J Immunol; 1996 Aug; 157(4):1758-72. PubMed ID: 8759766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic rearranged T cell receptor gene inhibits lymphadenopathy and accumulation of CD4-CD8-B220+ T cells in lpr/lpr mice.
    Mountz JD; Zhou T; Eldridge J; Berry K; Blüthmann H
    J Exp Med; 1990 Dec; 172(6):1805-17. PubMed ID: 1701823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular inflammation in MRL/Mp-lpr/lpr mice.
    Jabs DA; Prendergast RA
    Invest Ophthalmol Vis Sci; 1991 May; 32(6):1944-7. PubMed ID: 2032814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
    Takahashi T; Yagi T; Kakinuma S; Kurokawa A; Okada T; Takatsu K; Aizawa S; Katagiri T
    J Immunol; 1997 Sep; 159(5):2532-41. PubMed ID: 9278347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver is a possible site for the proliferation of abnormal CD3+4-8- double-negative lymphocytes in autoimmune MRL-lpr/lpr mice.
    Ohteki T; Seki S; Abo T; Kumagai K
    J Exp Med; 1990 Jul; 172(1):7-12. PubMed ID: 2141631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association of V beta 8+ T cells with lupus-like syndrome in MRL-lpr/lpr mice.
    Fossati L; Merino R; Iwamoto M; Lemoine R; Izui S
    Eur J Immunol; 1994 Jul; 24(7):1717-20. PubMed ID: 8026533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoreactivity accelerates the development of autoimmunity and lymphoproliferation in MRL/Mp-lpr/lpr mice.
    Weston KM; Yeh ET; Sy MS
    J Immunol; 1987 Aug; 139(3):734-42. PubMed ID: 3110283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of mortality and lymphadenopathy in MRL-lpr/lpr mice treated with nonmitogenic anti-CD3 monoclonal antibody.
    Henrickson M; Giannini EH; Hirsch R
    Arthritis Rheum; 1994 Apr; 37(4):587-94. PubMed ID: 8147938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.